Humacyte Q4 EPS $(0.24), Inline; Humacyte Says Its Cash And Cash Equivalents Of $80.4M, Net Proceeds Of $43.1M From The March Offering And Additional Draw Of $20M Under The Oberland Funding Arrangement, Will Provide Cash Runway For At Least 12 Months
Benzinga Newsdesk - Mar 22, 2024, 7:04AM